Gastroesophageal Reflux Disease (GERD) is a common yet complex condition, affecting nearly 20% of the Western population. Its diagnosis and treatment require a comprehensive understanding of its pathophysiology and the latest therapeutic approaches.
GERD diagnosis is primarily clinical, relying heavily on patient-reported symptoms. However, objective tests like endoscopy, esophageal manometry, and ambulatory pH monitoring can provide valuable insight. Endoscopy is useful in assessing mucosal damage and excluding other disorders. Esophageal manometry evaluates esophageal motility, while ambulatory pH monitoring measures acid exposure in the esophagus, confirming the diagnosis in equivocal cases.
Proton pump inhibitors (PPIs) are the mainstay of GERD treatment, providing symptom relief and healing esophagitis. However, a subset of patients may not respond adequately to PPIs, necessitating the exploration of alternative therapeutic strategies.
For patients with refractory GERD, surgical interventions such as laparoscopic Nissen fundoplication can provide long-term symptom relief. Recent advancements also include minimally invasive endoscopic techniques like Stretta and Transoral Incisionless Fundoplication (TIF). These procedures aim to augment the lower esophageal sphincter, reducing gastroesophageal reflux.
Emerging therapies for GERD include novel pharmacological agents targeting different pathophysiological mechanisms, such as reflux inhibitors and esophageal mucosal protectants. Additionally, the role of dietary interventions and gut microbiota modulation in GERD management is increasingly recognized and warrants further research.
GERD is a multifaceted disorder with a broad spectrum of clinical presentations. Its effective management requires a comprehensive approach, incorporating accurate diagnosis, optimal use of pharmacotherapy, and consideration of advanced treatment options in refractory cases. As our understanding of GERD pathophysiology expands, it paves the way for novel therapeutic strategies, promising improved patient outcomes.
1.
Research discovery halts childhood brain tumor before it forms
2.
Increased Data Support Active Monitoring for Low-Risk Prostate Cancer.
3.
'CDC Must Be Investigated'; David Lynch, Bob Uecker Die; Nasal Epinephrine Warning
4.
Increasing Access to Prostate Cancer Drugs; Reducing Toxic Emissions; FTC Files a 'Charity' Suit.
5.
Infections the Main Cause of Nonrelapse Mortality After CAR-T for Blood Cancers
1.
Beyond the Blinders: A Review of Targeted Therapeutic Strategies for Triple-Negative Breast Cancer in 2025
2.
AI-Based Cancer Follow-Up Monitoring: Transforming Survivorship Care through Intelligent Surveillance
3.
Preventing Sarcopenia During Cancer Treatment
4.
Guidance for Managing Complex Anticoagulation
5.
Unlocking the Potential of Sarclisa: A New Hope for Cancer Treatment
1.
International Cancer Conference
2.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
3.
International Cancer Conference
4.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Updates on Standard V/S High Risk Myeloma Treatment
2.
Navigating the Complexities of Ph Negative ALL - Part XIV
3.
Current Scenario of Blood Cancer- A Conclusion on Genomic Testing & Advancement in Diagnosis and Treatment
4.
Advances in Classification/ Risk Stratification of Plasma Cell Dyscrasias
5.
Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part I
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation